Status:
COMPLETED
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Chronic Myelogenous Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this exploratory study will be to examine changes in chronic low grade chronic adverse events, measured by Common Terminology Criteria for Adverse Events (CTCAE) grading, when patients ...
Eligibility Criteria
Inclusion
- Male or female patients ≥ 18 years of age
- Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2
- Diagnosis of CML-CP associated with Bcr-Abl quantifiable by RQ-PCR (IS)
- Patients must be an imatinib responder and achieved the following efficacy milestones as appropriate for the length of time on imatinib therapy as per protocol
- CML-CP patients initiated on any dose of imatinib
- Ability to provide written informed consent prior to any study related screening procedures being done
Exclusion
- Loss of CHR or cytogenetic response
- Prior accelerated phase or blast phase CML
- Previously documented T315I mutation
- Presence of chromosomal abnormalities (trisomy 8) and/or clonal evolution other than Ph+.
- Previous treatment with any other tyrosine kinase inhibitor except for imatinib.
- Treatment with other investigational agents within 30 days of Day 1.
- History of non-compliance to medical regimens or inability to grant consent.
- Women who are pregnant, breast feeding, or of childbearing potential without a negative serum test at baseline. Male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and 3 months following discontinuation of study drug. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinib.
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00980018
Start Date
December 1 2009
End Date
December 1 2012
Last Update
July 1 2021
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Highlands Oncology Group
Fayetteville, Arkansas, United States, 72703
2
Hematology Oncology Services of Arkansas SC
Little Rock, Arkansas, United States, 72205
3
USC Norris Cancer Center LAC & USC Medical Center
Los Angeles, California, United States, 90033
4
Southwest Cancer Care Murrieta
Poway, California, United States, 92064